The [[alpha].sub.1] subunit isoforms include A, B, C, D, E, and G, encoded by CACNA1A,
CACNA1B, CACNA1C, CACNA1D, CACNA1E, and CACNA1G genes, respectively.
CACNA1B ([Ca.sub.v]2.2) is the only member in N-type VGCC family, and CACNA1B ([Ca.sub.v]2.2) overexpression has been detected in breast and prostate cancer [15], and it represents a novel therapeutic target for the treatment of breast and prostate cancer.
In the current study, we determined both mRNA and protein expression of CACNA1B ([Ca.sub.v]2.2) in NSCLC tissue samples by quantitative reverse transcription PCR (qRT-PCR) and tissue microarray immunohistochemistry analysis (TMA-IHC), respectively, and correlated to patients' clinical characteristics and overall survival.
CACNA1B ([Ca.sub.v]2.2) mRNA and Protein Expression and Statistical Analysis.
Student's t-test was used to compare CACNA1B ([Ca.sub.v]2.2) mRNA and protein expression between tumorous and nontumorous tissue samples.
CACNA1B ([Ca.sub.v]2.2) mRNA Level Was Significantly Higher in NSCLC Tumorous Tissues than in Adjacent Nontumorous Tissues.
CACNA1B ([Ca.sub.v]2.2) Protein Level Was Significantly Higher in NSCLC Tumorous Tissues than in Adjacent Nontumorous Tissues.
Association of CACNA1B ([Ca.sub.v]2.2) Expression with NSCLC Clinical Characteristics.
High CACNA1B ([Ca.sub.v]2.2) Expression Predicts Poor Overall Survival in NSCLC Patients.
In the current study, we determined mRNA and protein expression levels of CACNA1B ([Ca.sub.v]2.2) in both NSCLC tumorous and adjacent nontumorous tissues.
CACNA1B ([Ca.sub.v]2.2) is an N-type VGCC and expressed in the brain and the peripheral nervous system.